Skip to Content
Merck
All Photos(1)

Documents

Y0000774

Lansoprazole for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Lansoprazole

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H14F3N3O2S
CAS Number:
103577-45-3
Molecular Weight:
369.36
MDL number:
MFCD00866873
UNSPSC Code:
41116107
PubChem Substance ID:
329831144
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

lansoprazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

InChI key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

Gene Information

human ... ATP4A(495) , ATP4B(496)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lansoprazole for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000773

Lansoprazole, European Pharmacopoeia (EP) Reference Standard

1356916

Lansoprazole, United States Pharmacopeia (USP) Reference Standard

1356927

Lansoprazole Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1390

Lansoprazole, Pharmaceutical Secondary Standard; Certified Reference Material

1356931

Lansoprazole Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP872

Lansoprazole, British Pharmacopoeia (BP) Reference Standard

BP873

Lansoprazole impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR3019

Lansoprazole Related Compound A, pharmaceutical secondary standard, certified reference material

PHR2956

Lansoprazole Related Compound B, certified reference material, pharmaceutical secondary standard

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yun Jeong Lim et al.
Digestion, 86(2), 171-177 (2012-08-22)
Proton pump inhibitors (PPIs) are widely used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers. NSAIDs produce small intestinal injury and some PPIs have been reported to protect against NSAID-induced small bowel injury in rats. The aim of this study
Hiroshi Satoh
Current pharmaceutical design, 19(1), 67-75 (2012-09-07)
The proton pump inhibitors (PPIs) lansoprazole (LPZ) and omeprazole (OPZ) have been widely used for more than 20 years in the treatment of acid-related diseases such as gastro-duodenal ulcers and reflux esophagitis. Both LPZ and OPZ are derivatives of 2-[(2-
Grace Chai et al.
Pediatrics, 130(1), 23-31 (2012-06-20)
To describe trends in outpatient prescription drug utilization in US children and the changes in major areas of pediatric therapeutic use for the years 2002 through 2010. Large prescription databases (the IMS Vector One: National and Total Patient Tracker) were
Jun-Won Chung et al.
Journal of gastroenterology and hepatology, 27(11), 1675-1680 (2012-08-02)
Increased resistance of Helicobacter pylori to antibiotics has increased the need to develop new first-line treatments for H. pylori. We have prospectively evaluated 10-day sequential versus conventional triple therapy in peptic ulcer patients. One hundred and fifty-nine patients with peptic ulcer
Jyh-Ming Liou et al.
Lancet (London, England), 381(9862), 205-213 (2012-11-20)
Whether sequential treatment can replace triple therapy as the standard treatment for Helicobacter pylori infection is unknown. We compared the efficacy of sequential treatment for 10 days and 14 days with triple therapy for 14 days in first-line treatment. For
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service